COMPARATIVE TRANSCRIPTOMIC PROFILING REVEALS CONSISTENT GENE EXPRESSION SIGNATURES ASSOCIATED WITH BREAST CANCER ACROSS INDEPENDENT COHORTS

Authors

DOI:

https://doi.org/10.67772/b85k9v50

Keywords:

Breast cancer, Cross-cohort analysis, Gene expression, Transcriptomics, Molecular signatures

Abstract

Breast cancer exhibits substantial molecular heterogeneity that can limit the reproducibility of transcriptomic biomarkers across independent patient cohorts. This study performed a cross-cohort transcriptomic analysis to identify robust gene-expression signatures associated with breast cancer. Three independent datasets, BC-TCGA, GSE2034, and GSE25066, comprising 1,368 samples were analyzed after gene-identifier harmonization, yielding 10,351 genes shared across all cohorts. Principal component analysis demonstrated strong transcriptional separation in BC-TCGA, moderate separation in GSE25066, and substantial overlap in GSE2034. Differential-expression analysis identified 12,856, 32, and 2,889 FDR-significant genes in BC-TCGA, GSE2034, and GSE25066, respectively. Applying an additional standardized effect-size threshold (|Hedges’ g| ≥ 0.50) identified 374 genes supported by at least two cohorts, of which 164 exhibited concordant directional effects. Most concordant genes (163) were reproduced between BC-TCGA and GSE25066, whereas no gene fulfilled stringent reproducibility criteria across all three cohorts. Prominent candidates included SFRP1, NFIB, GATA3, CCND1, FOXC1, KRT18, and UGP2. These findings demonstrate substantial cohort-dependent transcriptional heterogeneity and highlight the importance of effect-size-aware cross-cohort validation for prioritizing robust breast cancer molecular signatures for subsequent functional and clinical investigation.

References

1.Guo, L., Kong, D., Liu, J., Zhan, L., Luo, L., Zheng, W., ... & Sun, S. (2023). Breast cancer heterogeneity and its implication in personalized precision therapy. Experimental hematology & oncology, 12(1), 3.

2.Turner, K. M., Yeo, S. K., Holm, T. M., Shaughnessy, E., & Guan, J. L. (2021). Heterogeneity within molecular subtypes of breast cancer. American Journal of Physiology-Cell Physiology, 321(2), C343-C354.

3.Lüönd, F., Tiede, S., & Christofori, G. (2021). Breast cancer as an example of tumour heterogeneity and tumour cell plasticity during malignant progression. British journal of cancer, 125(2), 164-175.

4.Supplitt, S., Karpinski, P., Sasiadek, M., & Laczmanska, I. (2021). Current achievements and applications of transcriptomics in personalized cancer medicine. International journal of molecular sciences, 22(3), 1422.

5.Ghoussaini, M., Mountjoy, E., Carmona, M., Peat, G., Schmidt, E. M., Hercules, A., ... & Dunham, I. (2021). Open Targets Genetics: systematic identification of trait-associated genes using large-scale genetics and functional genomics. Nucleic acids research, 49(D1), D1311-D1320.

6.Zhao, Z., Zhang, K. N., Wang, Q., Li, G., Zeng, F., Zhang, Y., ... & Jiang, T. (2021). Chinese Glioma Genome Atlas (CGGA): a comprehensive resource with functional genomic data from Chinese glioma patients. Genomics, proteomics & bioinformatics, 19(1), 1-12.

7.Chan, M. Y., Efthymios, M., Tan, S. H., Pickering, J. W., Troughton, R., Pemberton, C., ... & Richards, A. M. (2020). Prioritizing candidates of post–myocardial infarction heart failure using plasma proteomics and single-cell transcriptomics. Circulation, 142(15), 1408-1421.

8.Zhou, K., Zhang, M., Zhai, D., Wang, Z., Liu, T., Xie, Y., ... & Lin, Y. (2024). Genomic and transcriptomic profiling of inflammatory breast cancer reveals distinct molecular characteristics to non-inflammatory breast cancers. Breast Cancer Research and Treatment, 208(2), 441-459.

9.Caswell-Jin, J. L., Lorenz, C., & Curtis, C. (2021). Molecular heterogeneity and evolution in breast cancer. Annual Review of Cancer Biology, 5(1), 79-94.

10.Baliu-Piqué, M., Pandiella, A., & Ocana, A. (2020). Breast cancer heterogeneity and response to novel therapeutics. Cancers, 12(11), 3271.

11.Carlino, F., Solinas, C., Orditura, M., Bisceglia, M. D., Pellegrino, B., & Diana, A. (2024). Heterogeneity in breast cancer: clinical and therapeutic implications. Frontiers in oncology, 14, 1321654.

12.Abba, M. C., Drake, J. A., Hawkins, K. A., Hu, Y., Sun, H., Notcovich, C., ... & Aldaz, C. M. (2004). Transcriptomic changes in human breast cancer progression as determined by serial analysis of gene expression. Breast Cancer Research, 6(5), R499.

13.Eswaran, J., Cyanam, D., Mudvari, P., Reddy, S. D. N., Pakala, S. B., Nair, S. S., ... & Kumar, R. (2012). Transcriptomic landscape of breast cancers through mRNA sequencing. Scientific reports, 2(1), 264.

14.Smid, M., Rodríguez-González, F. G., Sieuwerts, A. M., Salgado, R., Prager-Van der Smissen, W. J., Vlugt-Daane, M. V. D., ... & Martens, J. W. (2016). Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration. Nature communications, 7(1), 12910.

15.Vishnubalaji, R., Sasidharan Nair, V., Ouararhni, K., Elkord, E., & Alajez, N. M. (2019). Integrated transcriptome and pathway analyses revealed multiple activated pathways in breast cancer. Frontiers in oncology, 9, 476320.

16.Haynes, W. A., Vallania, F., Liu, C., Bongen, E., Tomczak, A., Andres-Terrè, M., ... & Khatri, P. (2017). Empowering multi-cohort gene expression analysis to increase reproducibility. In Pacific symposium on biocomputing 2017 (pp. 144-153).

17.Sweeney, T. E., Haynes, W. A., Vallania, F., Ioannidis, J. P., & Khatri, P. (2017). Methods to increase reproducibility in differential gene expression via meta-analysis. Nucleic acids research, 45(1), e1-e1.

18.Siavoshi, A., Taghizadeh, M., Dookhe, E., & Piran, M. (2022). Gene expression profiles and pathway enrichment analysis to identification of differentially expressed gene and signaling pathways in epithelial ovarian cancer based on high-throughput RNA-seq data. Genomics, 114(1), 161-170.

19.Zhuang, D. Y., Jiang, L. I., He, Q. Q., Zhou, P., & Yue, T. (2015). Identification of hub subnetwork based on topological features of genes in breast cancer. International Journal of Molecular Medicine, 35(3), 664-674.

20.Marcotte, R., Sayad, A., Brown, K. R., Sanchez-Garcia, F., Reimand, J., Haider, M., ... & Neel, B. G. (2016). Functional genomic landscape of human breast cancer drivers, vulnerabilities, and resistance. Cell, 164(1), 293-309.

21.Korkola, J., & Gray, J. W. (2010). Breast cancer genomes—form and function. Current opinion in genetics & development, 20(1), 4-14.

22.Yoshimaru, T., Nakamura, Y., & Katagiri, T. (2021). Functional genomics for breast cancer drug target discovery. Journal of human genetics, 66(9), 927-935.

Xie, Haozhe; Li, Jie; Jatkoe, Tim; Hatzis, Christos (2017), “Gene Expression Profiles of Breast Cancer”, Mendeley Data, V1, doi: 10.17632/v3cc2p38hb.1

Downloads

Published

2026-10-24